Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Kyaw Thein

Assistant Professor

Oregon Health & Science University

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

.

ORCID

.

LinkedIn

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI

Contact this professor

LinkedIn

ORCID Google Scholar

Research Interests

Pharmacotherapy

60%

Pharmacology

30%

Oncology

60%

Targeted Therapy

50%

Chemoprevention

30%

Thrombosis

30%

Cancer Therapy

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles14

A systematic review and meta-analysis of phase III randomized controlled trials to assess the risk of pneumonia, URTIs, and VTE in multiple myeloma patients treated with isatuximab

Year:

2025

Target-Driven Tissue-Agnostic Drug Approvals—A New Path of Drug Development

Year:

2024

Histology Agnostic Drug Development: An Updated Review

Year:

2024

Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions

Year:

2024

Updated meta-analysis of randomized controlled trials on primary outpatient thromboprophylaxis in patients with gastric and gastroesophageal junction cancers receiving chemotherapy

Year:

2023

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer

Year:

2022

Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?

Year:

2022

Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with ovarian cancer receiving chemotherapy

Year:

2022

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers

Year:

2022

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study

Year:

2022

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study

Year:

2022

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study

Year:

2022

Thrombotic events in patients using cyclin dependent kinase 4/6 inhibitors, analysis of existing ambulatory risk assessment models and the potential influences of tumor specific risk factors

Year:

2022

Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy

Year:

2022

Collaborators6

Janos Roszik

The University of Texas MD Anderson Cancer Center

UNITED STATES

Scott E. Kopetz

The University of Texas MD Anderson Cancer Center

UNITED STATES

Malinda West

Assistant Professor of Medicine

University of Wisconsin-Madison

UNITED STATES

Bettzy Stephen

The University of Texas MD Anderson Cancer Center

UNITED STATES

Sarina Piha-Paul

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

Thein Hlaing Oo

The University of Texas MD Anderson Cancer Center

UNITED STATES

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI